• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Mr. M
Dr. Migliore I step off the subway, up the elevator, and up several flights of stairs. There’s a homeless man there who always uses the last stair of the lower staircase as a tray for his food. And by tray, I mean he sets his half-eaten rice burrito directly onto the step and picks around at it while I imagine the guacamole is mixing with Hep B and C. diff and MRSA. He looks up at me, I promise myself for the 100th time I’m going to start carrying cash or Kind bars or something; I give him my best sheepish face, and emerge at street level. I walk toward my hospital and pass a gentleman who sits on a ledge next to the ...
Source: The Hospitalist - December 1, 2022 Category: Hospital Management Authors: Lisa Casinger Tags: Essay Source Type: research

Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: a French population-based study on prostate cancer patients
CONCLUSION: Our study provides knowledge on abiraterone and enzalutamide real-life safety profiles, especially for events leading to hospitalisation. Despite several limitations, including the lack of clinical data, the safety signal for AKI under abiraterone is in line with results of an analysis of the French pharmacovigilance database, which requires further specific investigations. Enlightening the clinicians' therapeutic choices for patients treated for prostate cancer, our study should lead to clinicians to be cautious in the use of abiraterone.PMID:34224605 | DOI:10.1111/bcp.14972
Source: Clinical Prostate Cancer - July 5, 2021 Category: Cancer & Oncology Authors: Lucie-Marie Scailteux Fabien Despas Fr édéric Balusson Boris Campillo-Gimenez Romain Mathieu S ébastien Vincendeau Andr é Happe Emmanuel Nowak Sandrine Kerbrat Emmanuel Oger Source Type: research

Adverse drug reactions profiles for abiraterone and enzalutamide: A pharmacovigilance descriptive analysis.
CONCLUSION: The analysis of the French pharmacovigilance database cases allows to confirm an expected and monitored risk profile in the risk management plan for both drugs. Several signals have arisen, some of which will be investigated through a pharmacoepidemiology study. PMID: 33376005 [PubMed - as supplied by publisher]
Source: Therapie - December 13, 2020 Category: Psychiatry & Psychology Authors: Scailteux LM, Lacroix C, Bergeron S, Despas F, Sassier M, Triquet L, Picard S, Oger E, Polard E, et le réseau français des Centres régionaux de pharmacovigilance Tags: Therapie Source Type: research

The Paradoxical Protective Effect of Liver Steatosis on Severity and Functional Outcome of Ischemic Stroke
Conclusions: Our study shows that a higher burden of liver steatosis seems to be associated with less severe stroke and better functional outcome after ischemic stroke or TIA. Introduction Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases from simple steatosis to steatohepatitis with varying degree of fibrosis, and liver cirrhosis (1, 2). NAFLD is becoming the most common chronic liver disease worldwide including Korea, affecting approximately 25% of the general population (3, 4). NAFLD is closely associated with obesity, insulin resistance, and type 2 diabetes mellitus, and is even recognized as ...
Source: Frontiers in Neurology - April 11, 2019 Category: Neurology Source Type: research

Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
CONCLUSION: A 63-year-old man on a stable dose of warfarin experienced a decrease in INR values after the initiation of a 12-week course of sofosbuvir and ribavirin for the treatment of chronic HCV infection. PMID: 28596225 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - June 11, 2017 Category: Drugs & Pharmacology Authors: Peterson D, Van Ermen A Tags: Am J Health Syst Pharm Source Type: research

Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment.
We report a case of dabigatran intoxication in an elderly man affected by heart failure and worsening renal function, who developed acute hepatitis and coma, which was successfully treated with continuous veno-venous hemodiafiltration. Although extracorporeal therapy has been suggested as a strategy for clearing dabigatran during acute bleeding, this approach may be useful in other dabigatran-related, life-threatening conditions, such as that described in this report. PMID: 27910004 [PubMed - as supplied by publisher]
Source: International Journal of Hematology - November 30, 2016 Category: Hematology Authors: Porru M, Mameli A, Cianchetti ME, Musu M, Schirru P, Ruberto MF, Barcellona D, Marongiu F Tags: Int J Hematol Source Type: research

Reversing the effects of the new anti-clotting drugs
The oral anticoagulant warfarin (Coumadin) became available for prescription in 1954. This anti-clotting drug commanded national attention when President Dwight Eisenhower received the drug as part of his treatment following a heart attack. No other oral anticoagulant was successfully developed and marketed in the United States until 2010. Warfarin is a dangerous drug. Along with insulin, it is responsible for the most emergency hospitalizations due to adverse drug reactions. Whereas insulin causes low blood sugar, warfarin is notorious for the complication of major bleeding. Warfarin is plagued by hundreds of drug-drug an...
Source: New Harvard Health Information - December 9, 2015 Category: Consumer Health News Authors: Samuel Z. Goldhaber, MD Tags: Drugs and Supplements Health Heart Health Hypertension and Stroke anti-clotting coumadin deep-vein-thrombosis DVT Source Type: news

EBN resources page
SIGN Apps for iPhone and iPad http://itunes.com/apps/signguidelines, https://play.google.com/store/apps/details?id=com.rootcreative.sign The SIGN app has recently been updated and now contains quick reference guides (QRGs) for:SIGN 136 Management of chronic pain SIGN 135 Management of epithelial ovarian cancer SIGN 134 Treatment of primary breast cancer SIGN 133 Management of hepatitis C The SIGN app has also had a complete re-design and now features:Optimisation for the latest operating systems Re-designed for improved legibility Send pdf button feature Split screen feature (ipad) Prevention of stroke in patients with atr...
Source: Evidence-Based Nursing - June 17, 2014 Category: Nursing Tags: Liver disease, General practice / family medicine, Hepatitis and other GI infections, Drugs: cardiovascular system, Pain (neurology), Stroke, Diet, Pregnancy, Reproductive medicine, Breast cancer, Gynecological cancer, Lung cancer (oncology), Radiotherapy Source Type: research

Hepatitis C and recurrent treatment-resistant acute ischemic stroke.
Abstract Since the introduction of recombinant tissue plasminogen activator and thrombolysis, acute ischemic stroke has become a treatable disorder if the patient presents within the 4.5-hour time window. Typically, sporadic stroke is caused by atherosclerotic disease involving large or small cerebral arteries or secondary to a cardioembolic source often associated with atrial fibrillation. In the over-65-year age group, more rare causes of stroke, such as antiphospholipid syndromes, are unusual; such stroke etiologies are mostly seen in a younger age group (<55 years). Here we describe acute ischemic stroke in...
Source: Baylor University Medical Center Proceedings - April 1, 2013 Category: Universities & Medical Training Authors: Saxsena A, Tarsia J, Dunn C, Aysenne A, Shah B, Moore DF Tags: Proc (Bayl Univ Med Cent) Source Type: research